RA with hand arthritises
Conditions
Interventions
investigational material(s)
Generic name etc : KENACORT-A
INN of investigational material : Triamcinolone Acetonide
Therapeutic category code : 245 Adrenal hormone preparations
Dosage and Administrati
Sponsors
Kamagaya General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) joint rheumatic with hand arthritises (sharp pain VAS :5, more than) 2) on the back and the enough understanding which had the enough explanation in case of participation of a study and more than 20-year-old patient who could get consent by free will of the patient person himself by a document
Exclusion criteria
Exclusion criteria: 1) the patient who has the medical history of the hyperesthesia to an ingredient of this pill 2) patient with infection in which effective anti-fungus agent doesn't exist and mycosis of the whole body 3) patient of peptic ulcer 4) patient with psychiatric disorder 5) tuberculosis, disease patient 6) simple herpes, patient with keratitis Patient of a vesica cataract behind the 7) 8) patient of glaucoma 9) patient of high blood pressure 10) patient with electrolyte abnormality 11) patient with thrombosis 12) the patient with a surgical wound of internal organs who went recently 13) the patient who has caused acute myocardial infarction 14) the following one of parts are the patient who is a prescription target. 1. In the synovial cavity with an infection, in the synovial bursa, in the tendon sheath or around the tendon 2. In the synovial cavity of a disturbed joint 15) pregnant woman, lactating woman and patient with a possibility that I'm pregnant 16) a doctor in attendance is the patient who judged that participation in this research was unsuitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety efficacy Sharp pain VAS which is 3 months after prescription | — |
Secondary
| Measure | Time frame |
|---|---|
| safety efficacy Sharp pain VAS which is a week and 1 month after prescription safety efficacy The carpal joint ultrasonic evaluation which are 1 month a week and 3 months after prescription (the synovial membrane limbation score and the synovial membrane bloodstream signal score) safety efficacy The inflammatory marker which are 1 month a week and 3 months after prescription (CRP, ESR, MMP-3 and RF) safety efficacy The disease activity which are 1 month a week and 3 months after prescription (DAS28 and CDAI) safety efficacy HAQ and the Quick DASH score which are 1 month a week and 3 months after prescription safety efficacy The carpal joint mobile area which are 1 month a week and 3 months after prescription (sekutsu and tenohirakutsu) safety efficacy Joint destruction by the carpal joint roentgen of 3 months later of prescription (in accordance with Sharp score) | — |
Countries
Japan
Outcome results
None listed